<DOC>
	<DOCNO>NCT01954108</DOCNO>
	<brief_summary>The primary objective study compare OSTENIL® TENDON ( 2 % hyaluronan ) Extracorporeal Shock Wave ( ESWT ) therapy treatment painful Achilles tendinopathy .</brief_summary>
	<brief_title>Hyaluronan Treatment Painful Achilles Tendinopathy .</brief_title>
	<detailed_description />
	<mesh_term>Tendinopathy</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Male female patient 18 75 year age . Good general health condition . Signed write informed consent . Painful Achilles midportion tendinopathy since equal 6 week . Pain accord VAS ( Huskisson , 100 mm ) equal 40 mm . Ensured compliance subject whole study period . Concomitant previous participation clinical investigation within last 3 month prior study inclusion . Infection relevant skin disease study relevant site . Blood coagulation disorder intake blood thinner ( e.g . Marcumar ) . Known hypersensitivity hyaluronic acid ( HA ) preparation constituent mannitol , sodium chloride , disodium phosphate sodium dihydrogenphosphate . Contraindications ESWT application study relevant area ( e.g . recent surgery , malignant tumour , local osteomyelitis open epiphysis ) . Severe intercurrent illness ( e.g . uncontrolled diabetes mellitus , peripheral neuropathy ) , opinion investigator , may put patient risk participate study , affect patient 's ability take part study . Concomitant disease study relevant site ( e.g . insertion tendinopathy Achilles tendon ) influencing study evaluation . Diseases characteristic judge investigator incompatible assessment and/or procedure study evaluation . Intake concomitant medication allow might interfere functional assessment study ( e.g . immunosuppressive drug within last 3 month ) . Previous therapy ( except nonsteroidal antiinflammatory drug ( NSAID ) ) study relevant site within last 4 week prior study inclusion . Use NSAIDs within last week prior study treatment . Recent history drug and/or alcohol abuse ( within last 6 month ) . Pregnant lactating female . Participants childbearing age ( premenopausal ) accept use method birth control pearl index least 1 ( i.e . oral contraceptive , vaginal ring , hormonereleasing Intrauterine Device ( IUD ) , implant , depot syrinx , hormone patch , double barrier method , tubal ligation , vasectomise partner , … ) treatment period first 4 week followup period . Subjects capable contract understanding nature , risk , significance implication clinical investigation unable form rational intention light fact . Subjects unable understand inform consent high probability non compliance study procedure / non completion study accord investigator 's judgement ( e.g . illiteracy , insufficient knowledge local language ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>tendinopathy</keyword>
	<keyword>hyaluronan</keyword>
	<keyword>tendon</keyword>
	<keyword>hyaluronic acid</keyword>
	<keyword>extracorporeal shock wave</keyword>
</DOC>